Indocyangreen Elimination in Cirrhosis and Acute Liver Failure

Completed

• Conditions: Acute Liver Failure; Liver Cirrhosis

• Registration Number: NCT00245310
• Lead Sponsor: Heidelberg University

Brief Summary

Indocyangreen (ICG)is totally biliary eliminated and corresponds to hepatocyte function and liver perfusion.

The ICG-clearance will be evaluated as a prognostic marker in liver disease.

Detailed Description

patients with acute liver failure or advanced liver disease will be studied. ICG-clearance will be correlated with established clinical scores and outcome.

Study Timeline

• Study Start: 2005-10
• Study First Submitted: 2005-10-25
• Study First Submitted QC: 2005-10-25
• Study First Posted: 2005-10-27
• Status Verified: 2008-11
• Primary Completion: 2010-10
• Study Completion: 2010-10
• Last Update Submitted: 2010-10-08
• Last Update Posted: 2010-10-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• acute liver failure OR end-stage liver disease
• normal hepatic perfusion by doppler ultrasound

Exclusion Criteria

• portal vein thrombosis
• allergy to ICG or iodine
• thyroid disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

University of Heidelberg; 🇩🇪 Heidelberg, Germany